The Asia Pacific Antibody Therapeutics Market would witness market growth of 15.3 % CAGR during the forecast period (2023-2030).
Antibody therapeutics are used in treating hematological disorders. For example, Rituximab is utilized in certain types of leukemia and lymphoma by targeting B cells. Additionally, antibodies like Eculizumab can inhibit the complement system, providing a treatment option for disorders such as paroxysmal nocturnal hemoglobinuria (PNH). These are being explored in neurological disorders. In conditions like multiple sclerosis, monoclonal antibodies such as Natalizumab and Ocrelizumab target immune cells involved in the disease process. Antibodies may also be investigated for their potential in neurodegenerative disorders like Alzheimer's disease. Antibody therapeutics are being researched for applications in cardiovascular diseases. Targeting specific factors involved in atherosclerosis or thrombosis, antibodies aim to reduce the risk of cardiovascular events. For instance, Evolocumab and Alirocumab target PCSK9 to lower cholesterol levels.
Antibody therapeutics are explored in gynecological conditions. Bevacizumab, for example, is used to treat certain gynecological cancers by inhibiting angiogenesis. In the realm of rare diseases, antibody therapeutics offer targeted solutions. For example, Eculizumab treats PNH, a rare blood disorder. Furthermore, bispecific antibodies, designed to bind to two targets simultaneously, are gaining prominence. These antibodies offer innovative therapeutic strategies by engaging multiple pathways or cell types. Bispecific antibodies can redirect immune cells to tumor cells, enhance target binding, or modulate dual signaling pathways. Advancements in bispecific antibody engineering are expanding their applications across various diseases.
According to the National Library of Medicine, asthma is a significant public health issue in China, with a national prevalence of 4.2%, or 45.7 million Chinese adults. The prevalence of asthma has been increasing globally, including in China. A considerable proportion of asthma cases are attributable to China's large and expanding population, emphasizing the criticality of effective and targeted treatment options. The enlargement of asthma cases necessitates a healthcare infrastructure ready to adopt and integrate innovative therapies in China. Advances in antibody engineering have resulted in the development of long-acting formulations, allowing for less frequent dosing in China. All these factors will uplift the regional market’s expansion in the coming years.
The China market dominated the Asia Pacific Antibody Therapeutics Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $47,019.6 million by 2030. The Japan market is showcasing a CAGR of 14.6% during (2023 - 2030). Additionally, The India market would register a CAGR of 16% during (2023 - 2030).
Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous, and Others. Based on Format, the market is segmented into Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody, Antibody fragment & Others. Based on Source, the market is segmented into Human, Humanized, and Chimeric. Based on End User, the market is segmented into Hospitals, Long-term care facilities, and Others. Based on Disease Areas, the market is segmented into Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology, Oncology, Infectious Diseases, Immunology, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include F. Hoffmann-La Roche Ltd, AbbVie, Inc., Johnson & Johnson (Johnson & Johnson Services, Inc.), Merck KGaA, Bristol Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Novartis AG, Biogen, Inc. and Amgen, Inc.
Antibody therapeutics are used in treating hematological disorders. For example, Rituximab is utilized in certain types of leukemia and lymphoma by targeting B cells. Additionally, antibodies like Eculizumab can inhibit the complement system, providing a treatment option for disorders such as paroxysmal nocturnal hemoglobinuria (PNH). These are being explored in neurological disorders. In conditions like multiple sclerosis, monoclonal antibodies such as Natalizumab and Ocrelizumab target immune cells involved in the disease process. Antibodies may also be investigated for their potential in neurodegenerative disorders like Alzheimer's disease. Antibody therapeutics are being researched for applications in cardiovascular diseases. Targeting specific factors involved in atherosclerosis or thrombosis, antibodies aim to reduce the risk of cardiovascular events. For instance, Evolocumab and Alirocumab target PCSK9 to lower cholesterol levels.
Antibody therapeutics are explored in gynecological conditions. Bevacizumab, for example, is used to treat certain gynecological cancers by inhibiting angiogenesis. In the realm of rare diseases, antibody therapeutics offer targeted solutions. For example, Eculizumab treats PNH, a rare blood disorder. Furthermore, bispecific antibodies, designed to bind to two targets simultaneously, are gaining prominence. These antibodies offer innovative therapeutic strategies by engaging multiple pathways or cell types. Bispecific antibodies can redirect immune cells to tumor cells, enhance target binding, or modulate dual signaling pathways. Advancements in bispecific antibody engineering are expanding their applications across various diseases.
According to the National Library of Medicine, asthma is a significant public health issue in China, with a national prevalence of 4.2%, or 45.7 million Chinese adults. The prevalence of asthma has been increasing globally, including in China. A considerable proportion of asthma cases are attributable to China's large and expanding population, emphasizing the criticality of effective and targeted treatment options. The enlargement of asthma cases necessitates a healthcare infrastructure ready to adopt and integrate innovative therapies in China. Advances in antibody engineering have resulted in the development of long-acting formulations, allowing for less frequent dosing in China. All these factors will uplift the regional market’s expansion in the coming years.
The China market dominated the Asia Pacific Antibody Therapeutics Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $47,019.6 million by 2030. The Japan market is showcasing a CAGR of 14.6% during (2023 - 2030). Additionally, The India market would register a CAGR of 16% during (2023 - 2030).
Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous, and Others. Based on Format, the market is segmented into Monoclonal Antibody, Polyclonal Antibody Therapy, Bispecific Antibody, Antibody fragment & Others. Based on Source, the market is segmented into Human, Humanized, and Chimeric. Based on End User, the market is segmented into Hospitals, Long-term care facilities, and Others. Based on Disease Areas, the market is segmented into Autoimmune & Inflammatory Diseases, Neurology, Osteology, Hematology, Oncology, Infectious Diseases, Immunology, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include F. Hoffmann-La Roche Ltd, AbbVie, Inc., Johnson & Johnson (Johnson & Johnson Services, Inc.), Merck KGaA, Bristol Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Novartis AG, Biogen, Inc. and Amgen, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Route of Administration- Intravenous
- Subcutaneous
- Others
- Monoclonal Antibody
- Polyclonal Antibody Therapy
- Bispecific Antibody
- Antibody fragment & Others
- Human
- Humanized
- Chimeric
- Hospitals
- Long-term care facilities
- Other
- Autoimmune & Inflammatory Diseases
- Neurology
- Osteology
- Hematology
- Oncology
- Infectious Diseases
- Immunology
- Others
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- F.Hoffmann-La Roche Ltd
- AbbVie, Inc.
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- Merck KGaA
- Bristol Myers Squibb Company
- AstraZeneca PLC
- Sanofi S.A.
- Novartis AG
- Biogen, Inc.
- Amgen, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. Asia Pacific Antibody Therapeutics Market by Route of Administration
Chapter 6. Asia Pacific Antibody Therapeutics Market by Format
Chapter 7. Asia Pacific Antibody Therapeutics Market by Source
Chapter 8. Asia Pacific Antibody Therapeutics Market by End User
Chapter 9. Asia Pacific Antibody Therapeutics Market by Disease Areas
Chapter 10. Asia Pacific Antibody Therapeutics Market by Country
Chapter 11. Company Profiles
Companies Mentioned
- F. Hoffmann-La Roche Ltd
- AbbVie, Inc.
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- Merck KGaA
- Bristol Myers Squibb Company
- AstraZeneca PLC
- Sanofi S.A.
- Novartis AG
- Biogen, Inc.
- Amgen, Inc.
Methodology
LOADING...
